Trial Profile

A Phase 1b/2 Study of BMS-986158 Monotherapy and in Combination With Either Ruxolitinib or Fedratinib in Participants With DIPSS-Intermediate or High Risk Myelofibrosis

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 25 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMS 986158 (Primary) ; Fedratinib (Primary) ; Ruxolitinib (Primary)
Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
Focus Adverse reactions
Sponsors Bristol-Myers Squibb

Most Recent Events

09 May 2024 Planned End Date changed from 26 Apr 2027 to 31 May 2026.
09 May 2024 Planned primary completion date changed from 14 Apr 2025 to 31 May 2026.
11 Mar 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com